A survey of reasons for continuing warfarin therapy in the era of direct oral anticoagulants in Japanese patients with atrial fibrillation: the SELECT study

References

• HataJTanizakiYKiyoharaYTen year recurrence after first ever stroke in a Japanese community: the Hisayama studyJ Neurol Neurosurg Psychiatry200576336837215716529
   PubMed Web of Science ®Google Scholar
• PereraKSVanasscheTBoschJESUS Global Registry Investigators. Global survey of the frequency of atrial fibrillation-associated stroke: embolic stroke of undetermined source global registryStroke20164792197220227507860
   PubMed Web of Science ®Google Scholar
• PrystowskyENBensonDWJrFusterVManagement of patients with atrial fibrillation. A statement for healthcare professionals. From the subcommittee on electrocardiography and electrophysiology, American Heart AssociationCirculation1996936126212778653857
   PubMed Web of Science ®Google Scholar
• WolfPAAbbottRDKannelWBAtrial fibrillation: a major contributor to stroke in the elderly. The Framingham StudyArch Intern Med19871479156115643632164
   PubMedGoogle Scholar
• BenjaminEJLevyDVaziriSMD’AgostinoRBBelangerAJWolfPAIndependent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart StudyJAMA1994271118408448114238
   PubMed Web of Science ®Google Scholar
• KokuboYWatanabeMHigashiyamaANakaoYMKusanoKMiyamotoYDevelopment of a basic risk score for incident atrial fibrillation in a Japanese general population – the Suita StudyCirc J201781111580158828539563
   PubMed Web of Science ®Google Scholar
• WangTJPariseHLevyDObesity and the risk of new-onset atrial fibrillationJAMA2004292202471247715562125
   PubMed Web of Science ®Google Scholar
• JanuaryCTWannLSAlpertJS2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm SocietyJ Am Coll Cardiol20146421e1e7624685669
   PubMed Web of Science ®Google Scholar
• KirchhofPBenussiSKotechaD2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEuropace201618111609167827567465
   PubMed Web of Science ®Google Scholar
• MozosIStoianDLucaCTCrosstalk between vitamins A, B12, D, K, C, and E status and arterial stiffnessDis Markers20172017878497128167849
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• LarsenTBRasmussenLHSkjøthFEfficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort studyJ Am Coll Cardiol201361222264227323562920
   PubMed Web of Science ®Google Scholar
• LaliberteFCloutierMNelsonWWReal-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patientsCurr Med Res Opin20143071317132524650301
   PubMed Web of Science ®Google Scholar
• HernandezIBaikSHPineraAZhangYRisk of bleeding with dabigatran in atrial fibrillationJAMA Intern Med20151751182425365537
   PubMed Web of Science ®Google Scholar
• LauffenburgerJCFarleyJFGehiAKRhoneyDHBrookhartMAFangGEffectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort studyJ Am Heart Assoc201544e00179825862791
   PubMed Web of Science ®Google Scholar
• BouillonKBertrandMMauraGBlotierePORicordeauPZureikMRisk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort studyLancet Haematol201524e150e15926687957
   PubMed Web of Science ®Google Scholar
• LipGYKeshishianAKambleSReal-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysisThromb Haemost2016116597598627538358
   PubMed Web of Science ®Google Scholar
• LipGYPanXKambleSMajor bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United StatesInt J Clin Pract201670975276327550177
   PubMed Web of Science ®Google Scholar
• JCS Joint Working GroupGuidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013)Circ J20147881997202124965079
   PubMed Web of Science ®Google Scholar
• YamaguchiTOptimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study GroupStroke200031481782110753981
   PubMed Web of Science ®Google Scholar
• YasakaMMinematsuKYamaguchiTOptimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillationIntern Med200140121183118811813841
   PubMed Web of Science ®Google Scholar
• BlechSEbnerTLudwig-SchwellingerEStangierJRothWThe metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humansDrug Metab Dispos200836238639918006647
   PubMed Web of Science ®Google Scholar
• StangierJRathgenKStähleHMazurDInfluence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre studyClin Pharmacokinet201049425926820214409
   PubMed Web of Science ®Google Scholar
• ParasrampuriaDATruittKEPharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor XaClin Pharmacokinet201655664165526620048
   PubMed Web of Science ®Google Scholar
• WeinzCSchwarzTKubitzaDMueckWLangDMetabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humansDrug Metab Dispos20093751056106419196845
   PubMed Web of Science ®Google Scholar
• FrostCWangJNepalSApixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsBr J Clin Pharmacol201375247648722759198
   PubMed Web of Science ®Google Scholar
• GiuglianoRPRuffCTBraunwaldEEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med2013369222093210424251359
   PubMed Web of Science ®Google Scholar
• HohnloserSHHijaziZThomasLEfficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trialEur Heart J201233222821283022933567
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
   PubMed Web of Science ®Google Scholar
• WangYKongMCLeeLHNgHJKoYKnowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulant controlThromb Res2014133455055424448058
   PubMed Web of Science ®Google Scholar
• ShoreSCareyEPTurakhiaMPAdherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administrationAm Heart J2014167681081724890529
   PubMed Web of Science ®Google Scholar
• AkaoMChunYHEsatoMFushimi AF Registry Investigators. Inappropriate use of oral anticoagulants for patients with atrial fibrillationCirc J20147892166217224976391
   PubMed Web of Science ®Google Scholar
• AkaoMChunYHWadaHFushimi AF Registry Investigators. Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF RegistryJ Cardiol201361426026623403369
   PubMed Web of Science ®Google Scholar
• AtarashiHInoueHOkumuraKYamashitaTKumagaiNOrigasaHJ-RHYTHM Registry InvestigatorsPresent status of anticoagulation treatment in Japanse patients with atrial fibrillation: a report from J-RHYTHM RegistryCirc J20117561328133321467664
   PubMed Web of Science ®Google Scholar
• AtarashiHInoueHOkumuraKYamashitaTOrigasaHJ-RHYTHM Registry InvestigatorsInvestigation of optimal anticoagulation strategy for stroke prevention in Japanse patients with atrial fibrillation – the J-RHYTHM Registry study designJ Cardiol2011571959920934857
   PubMed Web of Science ®Google Scholar
• KoretsuneYIkedaTKozumaKPatient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN studyPatient Prefer Adherence2017111987199629290682
   PubMed Web of Science ®Google Scholar